|
|
News Breaks | | | | January 26, 2013 | | 14:53 EDT |  | AMGN | Amgen supports state biosimilars initiatives focusing on patient safety
In conjunction with our oncology biosimilars partner Actavis' announcement earlier of our four oncology biosimilars products, Amgen stated that it supports state biosimilars initiatives that focus on sound science and patient safety. As a biotech company developing both innovator biologics and biosimilars, Amgen believes that patient safety does not stop at drug approval. "Amgen endorses state policies that would put patients first and, in doing so, increase confidence in the biosimilar pathway. It is important to have consistent policies in place at the federal and state level," said Scott Foraker, vice president and general manager of biosimilars at Amgen. | |
|
News For AMGN From The Last 14 Days Check below for free stories on AMGN the last two weeks. |
|
|
| May 13, 2013 | | 08:55 EDT |  | AMGN | Biosimiliar drug bill to be taken up in Senate, LA Times reports
 Subscribe for More Information | | | May 9, 2013 | | 16:48 EDT | | AMGN | Amgen, Zhejiang Beta Pharma announce joint venture in China
Subscribe for More Information | | | May 7, 2013 | | 16:31 EDT | | AMGN | Amgen announces Phase 3 head-to-head study of Vectibix versus Erbitux
Subscribe for More Information | | | May 6, 2013 | | 07:01 EDT | | AMGN | Transgenomic, Amgen sign collaboration agreement for CE-IVD CRC RAScan tests
Subscribe for More Information | |
|
|
|
|
|
|
